Views & Analysis Saving the jewel in the crown of ‘UKplc’: Brexit's impact on... Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.
Pharma Market Access Accelerated Access Review: no panacea for UK pharma What can the AAR do for the UK pharma industry, the health service and patients?
Articles Is the Cancer Drugs Fund beyond fixing? Barbara McLaughlan discusses England's Cancer Drugs Fund (CDF) and suggests ways of securing a new, sustainable assessment and funding model for cancer medicines.
Market Access The changing landscape of drug clinical assessment: Tommy Br... In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
